Methofill

Methotrexate, the active ingredient in Methofill, is an antimetabolite (folate antagonist) presented as an injectable solution for intravenous use. It is employed to manage autoimmune disorders and certain cancers in adult and pediatric patients. The drug interferes with DNA synthesis, reducing the proliferation of rapidly dividing cells, which underlies its efficacy in both inflammatory and malignant conditions.

GNH USA supplies Methofill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. Through a robust quality‑assured manufacturing process, the product meets European Union pharmacopoeial standards and is distributed to a global network of healthcare providers.

Methotrexate is used across several disease families, primarily autoimmune disorders and hematologic malignancies. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin plaque formation and severity. - Acute lymphoblastic leukemia: induces remission by inhibiting leukemic cell proliferation. - Non‑Hodgkin lymphoma: contributes to tumor control through cytotoxic activity. - Gestational trophoblastic disease: promotes resolution of trophoblastic tissue.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting. - Fatigue or weakness. - Mouth sores (stomatitis). - Mild elevation of liver enzymes. - Low white‑blood‑cell count (leukopenia).

Serious or Rare Side Effects: - Severe liver toxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Significant bone‑marrow suppression causing anemia. - Renal impairment. - Life‑threatening infections.

Before initiating methotrexate therapy, several safety considerations should be observed. - Baseline testing: obtain liver function, renal function and complete blood count before treatment. - Pregnancy contraindication: avoid use in pregnancy due to teratogenic risk; ensure effective contraception. - Monitoring: perform regular laboratory assessments to detect hepatotoxicity or marrow suppression. - Drug interactions: review concomitant medications, especially NSAIDs and other folate antagonists. - Patient education: advise on signs of infection, liver problems and pulmonary symptoms. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several agents that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Live vaccines: risk of severe infection due to immunosuppression. - High‑dose penicillins: reduce renal clearance of methotrexate.

Moderate Interactions (Monitor Closely): - Sulfonamide antibiotics: may potentiate hematologic toxicity. - Proton pump inhibitors: can affect renal elimination. - Trimethoprim‑sulfamethoxazole: increase risk of bone‑marrow suppression. - Alcohol: exacerbates liver toxicity.